Aflac stock stays supported by earnings momentum

Aflac stock stays supported by its latest reported earnings trend and market context. The company remains anchored by recurring insurance cash flows and a large investment portfolio.

Aflac Inc. stock (ISIN US0010551028) stays anchored by the companys earnings profile, with the latest available annual results showing $18.7 billion in total revenues, $4.1 billion in net earnings, and $6.42 in adjusted EPS for fiscal 2025. The company also reported a 15.2% return on equity for the year, according to its latest annual report on Aflac investor relations.

Fiscal 2025 numbers

The revenue base of $18.7 billion in fiscal 2025 compared with $17.4 billion in fiscal 2024, while net earnings rose from $3.8 billion to $4.1 billion over the same period. Adjusted EPS increased from $5.88 to $6.42 year over year, a clear quantified comparison that frames the stock around earnings delivery rather than headline noise.

That matters because AFLAC stock tends to trade more on underwriting discipline, investment income, and capital returns than on one-off product launches. The latest annual report also showed a dividend payout total of $1.6 billion in fiscal 2025, which remains a visible cash-use metric for income-focused shareholders.

Capital and returns

Aflac reported total assets of $116.9 billion at year-end 2025 and shareholders equity of $27.3 billion, both period-specific balance-sheet anchors that help explain why the insurer can keep returning capital while maintaining a large investment book. The companys ROE of 15.2% for fiscal 2025 adds a second operating marker to the earnings trend.

For the stock narrative, the important point is not a trading slogan but the combination of revenue growth, earnings growth, and capital efficiency. Revenue up 7.5% year over year, net earnings up 7.9%, and adjusted EPS up 9.2% together form the main evidence set around Aflacs latest reporting cycle.

Insurance cash engine

Aflacs core business remains supplemental health and life insurance, with Japan and the US still providing the central earnings mix. In fiscal 2025, premium and underwriting income continued to support the companys ability to fund dividends, buybacks, and investment income generation across a large fixed-income portfolio.

The product story is therefore straightforward: the company sells protection, collects recurring premiums, and converts a portion of that flow into capital returns. That model is reflected in the fiscal 2025 dividend total of $1.6 billion and the year-end equity base of $27.3 billion.

Latest market framing

The stock close is omitted because no reliable dated market quote is available in the current source set, so the more durable reference point is the companys fiscal 2025 report. In that report, Aflac paired $18.7 billion in revenue with $4.1 billion in net earnings and $6.42 in adjusted EPS, which is enough to frame the shares without leaning on an unverified intraday price.

For readers following AFLAC stock, the key evidence remains the 2025 earnings progression, the 15.2% ROE, and the $1.6 billion dividend total. Those three figures together show a business that is still defined by cash generation and capital discipline.

Aflac supplemental products

Aflacs supplemental health and cancer coverage products remain the best-known consumer-facing lines, and they sit at the center of the companys recurring premium base. The latest annual numbers show that the product mix still translates into scale, with $18.7 billion in revenue and $4.1 billion in net earnings in fiscal 2025.

Shareholder return profile

Aflac Inc. is a New York-listed insurer on the NYSE under AFL. Based on fiscal 2025 results, the stock case rests on earnings growth, a 15.2% return on equity, and continued dividend capacity rather than on a single event-driven catalyst.